Gene Editing, Gene Silencing and Marketing - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene Editing

Gene Silencing

Marketing

Laverock Therapeutics raises £13.5m to accelerate gene silencing platform

BioPharma Reporter

OCTOBER 2, 2023

Laverock Therapeutics, the gene editing-induced gene silencing platform for human therapeutic applications, has expanded its seed funding round to Â13.5 million.

Gene Silencing

Gene Silencing Gene Gene Editing Regulation

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Pharma Marketing Network

DECEMBER 21, 2020

those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., Am J Bioeth.

Genetics

Genetics Medicine Gene Therapy Marketing

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Laverock Therapeutics raises £13.5m to accelerate gene silencing platform

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Webinars

Stay Connected